Clinic, neuropathology and molecular genetics of frontotemporal dementia: a … – 7thSpace Interactive (press release)
By Dr. Matthew Watson
Clinic, neuropathology and molecular genetics of frontotemporal dementia: a ... 7thSpace Interactive (press release) Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review. Frontotemporal lobar degeneration (FTLD) represents a group of clinically, neuropathologically and genetically heterogeneous disorders with plenty of overlaps ... |
Opening new genetic windows on diagnosis – Siliconrepublic.com
By Dr. Matthew Watson
![]() Siliconrepublic.com | Opening new genetic windows on diagnosis Siliconrepublic.com Women make up the majority of the Molecular Genetics team at the National Centre for Medical Genetics in Dublin - 22 of the 25-strong team are female. Claire O'Connell finds out from Dr Aileen Butler how mining into genes can help patients get the ... |
Boston and ‘Lone Wolf’ Terrorism – UC Los Angeles
By Dr. Matthew Watson
Boston and 'Lone Wolf' Terrorism UC Los Angeles Los Angeles Magazine on Thursday featured a Q&A with Dr. Patrick Soon-Shiong, executive director of the UCLA Wireless Health Institute and a visiting professor of microbiology, immunology and molecular genetics, highlighting his career and his ... |
Heirlooms or not? – Muscatine Journal – Muscatine Journal
By Dr. Matthew Watson
Heirlooms or not? - Muscatine Journal Muscatine Journal Another term along with “heirloom” and “hybrid” is “genetically modified organisms” or (GMOs) which can be any plant, animal or microorganism which has been genetically altered using molecular genetics techniques such as gene cloning and protein ... |
Dr. Ted Ross of VGTI Florida to present ‘Novel Approaches to Vaccine Design’ – TCPalm
By Dr. Matthew Watson
Dr. Ted Ross of VGTI Florida to present 'Novel Approaches to Vaccine Design' TCPalm He previously was an associate professor in the Center for Vaccine Research and the Department of Microbiology and Molecular Genetics. He received his Ph.D. in microbiology and immunology from Vanderbilt University. He trained in HIV/AIDS and Vaccine ... |
Fish genome offers insights into evolution of land vertebrate – Hindustan Times
By Dr. Matthew Watson
![]() Hindustan Times | Fish genome offers insights into evolution of land vertebrate Hindustan Times Sequencing the coelacanth genome has been a long-sought goal and a major logistical milestone, said Chris Amemiya, PhD, Director of Molecular Genetics at the Benaroya Research Institute at Virginia Mason (BRI) and Professor of Biology at the University ... Coelacanth Genome: Unexpected Insights From Fish With A 300-million-year ...RedOrbit A*STAR Scientists Decipher Genome Code of a Living FossilSYS-CON Media (press release) |
Applied BioCode Appoints Michael Aye, Ph.D. as its Vice President of Molecular … – The Herald | HeraldOnline.com
By Dr. Matthew Watson
Applied BioCode Appoints Michael Aye, Ph.D. as its Vice President of Molecular ... The Herald | HeraldOnline.com Dr. Michael Aye has over 8 years of research and development experience at Focus Diagnostics, Inc. and Beckman Coulter, Inc. Prior to his industrial experience Dr. Aye has spent 10 years in academia focused on research in molecular genetics and ... |
Advocating for Women Scientists – BU Today
By Dr. Matthew Watson
![]() BU Today | Advocating for Women Scientists BU Today ... Institute and director of the Dana-Farber/Harvard Cancer Center, and Janet Rowley, the Blum-Riese Distinguished Service Professor of Medicine, of Molecular Genetics and Cell Biology, and of Human Genetics at the University of Chicago Medical Center. |
2013 Annual Regenerative Medicine Industry Report
By Dr. Matthew Watson
Tweet
The Alliance for Regenerative Medicine announced today the release of the 2013 annual regenerative medicine industry report. Here is the announcement in the Wall Street Journal online.
I'm proud to have been a part of putting it together and hope people find it useful. It is available for download on the ARM website here.
In addition to the complete download, ARM will make many of the figures, charts, tables and sections available for members to download and use in their own publications and presentations. Watch for these resources to be announced soon.
Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/yFBYKblnudk/2013-annual-regenerative-medicine.html
California Stem Cell Agency Budget Up 4.6 Percent, Topping $17 Million
By Dr. Matthew Watson
During the past couple of years, the California stem cell agency has vastly improved the way it
budgets the relatively tiny amount it spends on operational expenses.
operational budget was often all but incoherent to the public and to
at least some members of its governing board. (See here, here and
here.) But times have changed. The process for its operational
budget, which amounts to about $17 million for the 2013-14 fiscal
year, is now more transparent and better organized.
credited to the hiring of Matt Plunkett in December 2011 as its first
chief financial officer in its eight-year history, as well as the
efforts of CIRM directors Michael Goldberg and Marcy Feit. Goldberg,
a venture capitalist, is chairman of the board's Finance Subcommittee
and Feit, CEO of Valley Healthcare in Pleasanton, Ca., is vice chair. Plunkett, however,
left the agency suddenly last summer and the agency has no plans to
replace him. CIRM Chairman J.T. Thomas says Plunkett put new
financial systems in place that can be operated without a CFO.
what is upcoming for CIRM spending beginning in July in documents prepared for the Monday meeting of the governing board's Finance
Subcommittee meeting. The agenda, however, lacks a much-needed
explanation and justification for the spending. All that is presented
now for the public are raw numbers and a PowerPoint presentation,
which is no substitute for a nuanced, written overview.
budget proposed for 2013-14 stands at $17.4 million, up 4.6 percent, according to California Stem Cell Report calculations, or $771,000 from forecast expenditures for the current year. The
budget represents the cost of overseeing $1.8 billion in grants and
loans and preparing new proposals and reviews of applications for
hundreds of millions of dollars in additional awards.
personnel – $12.1 million, up from $10.7 million. Second largest
is outside contracting at $2 million, down from $2.9 million for the
current year, continuing a trend away from outside contracts, which
once were burgeoning.
meetings and workshops,”- which are expected to cost $1.8 million
this year. Next year, they are budgeted for $2 million. Some might
look askance at those sorts of expenditures for “meetings.”
However, that includes the fees and expenses for scientific reviewers
for multi-day meetings in the San Francisco area, which is a high
cost area, and other large gatherings. However, the figure does not
include travel for reviewers, who come from out of the state and even
from overseas.
three-day grant review session last September at the Claremont Hotel
in Oakland that cost $44,019. A two-day meeting at the same hotel for
the 29-member CIRM governing board cost $34,424. (These figures and others involving outside contracts can be found on the agenda of the
board's Governance Subcommittee meeting April 10.)
from different perspectives on expenditures. The spending plan
includes $2.0 million for the office of Chairman Thomas and $1.6
million for the office of President Alan Trounson. Comparable
figures for actual spending this fiscal year were not provided,
however, by CIRM for the Finance Subcommittee meeting. The size of
the chairman's budget reflects the controversial dual executive nature of management at CIRM, which has come under repeated
criticism, including from the recent blue-ribbon report by the
Institute of Medicine.. However, the arrangement is locked into state
law as the result of the ballot measure, Proposition 71, that created
the stem cell agency in 2004.
million with public relations and communications running slightly
more than $1 million. The scientific office, as one might expect,
consumes much larger amounts, with basic research, translational
research, grants review and grants administration budgeted at $4.7
million. The development side of the scientific office, which
focuses on pre–clinical and clinical research, is slated for $3.4
million. The agency did not offer comparable figures for the current
year.
legally spend only 6 percent of its $3 billion in bond funding for operational
expenses. At one time the agency had a 50-person staff cap, but that
was altered several years ago by the legislature. The most recent
figures show it has 54 employees. However, this month's budget
documents did not list the number of staff for this year or next.
it expects to spend an additional $1 million a year for rent
beginning in 2015, when a free rent deal provided through the city of
San Francisco expires. The city put together a $18 million package to
attract the CIRM headquarters in a bidding war with other California
cities. The agency has never produced a public accounting of whether
it has received full value on the package.
approved by the Finance panel next week without significant changes
and then by the full board late in May.
Finance meeting at two locations in San Francisco one each in Irvine,
Pleasanton, La Jolla and Berkeley. Specific locations can be found onthe agenda.
Meager California Biotech Representation in Governor’s China Trip
By Dr. Matthew Watson
California Gov. Jerry Brown and a flying squad of business types visited China last week, beating the drum for the Golden State in an effort to raise billions of dollars in investments.
“I do not know how this set of delegates were selected. What I do know is that this is the first of several delegations of California business delegates going to China with Governor Brown, and that more trips are scheduled. The focus of this first trip is Energy and Environment, and this might be why there is no biotech delegates in this trip. I am quite sure that they will participate in the following trips.”
(Following the posting of this item, Ron Leuty of the San Francisco Business Times gave us a heads up on the latest on the site. He reported in March that Joinn Laboratories, a Chinese contract research organization, purchased the site. Leuty said that its plans are vague about future development, but that it may lease some of the space.)
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/x57uSahTPNI/meager-california-biotech.html
Why Tanzania must accelerate agricultural biotechnology research – Daily News
By Dr. Matthew Watson
![]() Daily News | Why Tanzania must accelerate agricultural biotechnology research Daily News WHEN Dr Joseph Ndunguru of M i k o c h e n i A g r i c u l t u r a l Research Institute speaks about cutting edge science, he does so with passion. He believes that such science is possible in Tanzania -- and that agricultural biotechnology remains the ... |
Maceda attributes stamina to stem cell therapy, malunggay pills
By Sykes24Tracey
By Christian V. Esguerra Philippine Daily Inquirer
Former Senator Ernesto Maceda. FILE PHOTO
AGOO, La Union, PhilippinesThanks to the wonders of science, the oldest candidate in the May 13 senatorial election has managed to keep up with the grueling campaign.
So far, 78-year-old former Senate President Ernesto Maceda said Friday, he has not gotten sick despite a tough campaign schedule that usually requires him to travel from one province to anotherall thanks to the stem cell therapy he got for P600,000 at a medical facility in Germany in March last year.
I am now convinced that my stem cell therapy is effective and thats the reason why Ive been able to keep up with the rigorous campaign schedule, he told reporters before climbing the campaign stage at the Eriguel compound.
Maceda said the therapy was relatively cheap, noting that it would have cost him around P2.5 million if he had it in the Philippines. And it was worth it, he said.
I feel 20 years younger, he said.
Maceda joined a growing list of aging politicians who have resorted to stem cell therapy. They include Senate President Juan Ponce Enrile, 89, and former President Joseph Estrada, who celebrated his 76th birthday Friday.
Responding to a question by a TV reporter, Vice President Jejomar Binay said he does not need it yet.
The UNA campaign schedule is no walk in the park.
See original here:
Maceda attributes stamina to stem cell therapy, malunggay pills
Vatican hosts conference on advancements in stem cell therapy – Video
By Sykes24Tracey
Vatican hosts conference on advancements in stem cell therapy
http://en.romereports.com.
By: romereports
See the original post here:
Vatican hosts conference on advancements in stem cell therapy - Video
Human Genetic Engineering: A Very Brief Introduction – RedOrbit
By Dr. Matthew Watson
![]() RedOrbit | Human Genetic Engineering: A Very Brief Introduction RedOrbit What exactly is human genetic engineering (HGE or HGM)? It's a simple question with a complex answer. According to the Association of Reproductive Health Professionals (ARHP), HGM is a process by which scientists and medical professionals alter the ... |
The Pros of Genetic Engineering: Why ‘Playing God’ Could Help The Human Race – RedOrbit
By Dr. Matthew Watson
![]() RedOrbit | The Pros of Genetic Engineering: Why 'Playing God' Could Help The Human Race RedOrbit Despite the frequently encountered argument that scientists are 'playing God' with nature, the pros of genetic engineering are numerous and significant. When discussing genetically modified organisms (GMO), it is important to note that the FDA and the ... GMO's Do you know what you're eating? Flounder in Tomatoes? Should food ...Cornwall Free News Protesters demonstrate at FDA against GMOsWJLA Genetically Modified Organisms Split Genes, and OpinionsWWNO |
Gwynne Dyer: Genetic engineering: Golden rice – Lincoln Journal Star
By Dr. Matthew Watson
![]() ThinkProgress | Gwynne Dyer: Genetic engineering: Golden rice Lincoln Journal Star Fourteen years ago, scientists developed a genetically engineered version of rice that would promote the production of vitamin A to counter blindness and other diseases in children in developing countries. In a few months, the Philippines will become ... GMO Rider: 'Monsanto Protection' or 'Farmer Sustainability'?Genetic Engineering News |
The Mystery about Cyanide Taste
By Dr. Matthew Watson
What is potassium cyanide??
A chemical compound with the chemical formula KCN is commonly known as the Potassium cyanide. This is a colorless crystalline compound, highly soluble in water and is similar in appearance as that of sugar. Potassium cyanide is considered to be highly toxic in nature. Potassium cyanide is considered to be one of the most deadly compounds being discovered till date.
Production of Potassium Cyanide:
Potassium Cyanide can be produced mainly by treating hydrogen cyanide in the presence of a fifty percent of an aqueous solution of potassium hydroxide. After that the aqueous solution is either evaporated in a vacuum or by treating the form amide in the presence of potassium hydroxide. On an average per year approximately fifty thousand tons of potassium cyanide are being produced all over the world.
Use of Potassium Cyanide:
Potassium Cyanide is mainly used for the purpose of electroplating, organic synthesis of a number of chemical compounds, gold mining and so on. In accordance with the large scale use of Potassium Cyanide, it is also used in smaller scale applications like in the jewelry manufacturing industry for chemical buffing and gliding. Other than those mentioned earlier, Potassium Cyanide is also used by the entomologists as it is an excellent killing agent, and it has the unique capability of causing minimum damage to the highly fragile specimens.
Mystery about Potassium Cyanide:
Since, the time of its invention, the biggest mystery that has been surrounded with Potassium Cyanide, is about the taste of it. Due to the fact that Potassium Cyanide is exceedingly poisonous substance and can cause death of a person in seconds, the taste of it has remained a mystery or a fact yet to be known to the world. Though, many researches and tests have been conducted to find the taste of Potassium Cyanide but none of them could come up with the appropriate result.
Different views about the taste of Potassium Cyanide:
There has been number of views among the scientists about the taste of the Potassium Cyanide, some of them are as follows:
· Since on hydrolysis of KCN, the resultant compound that are formed are KOH and HCN, which are strong base and weak base respectively, Potassium Cyanide is confirmed to be basic nature. Since at room temperature HCN is a gas which evolves and the solution is expected to have more KOH, so the taste of Potassium Cyanide is assumed to be bitter.
· Some, scientists who have died while finding the taste of Potassium cyanide, could only write the alphabet “S” before dying, so it is not conclusive whether it is sour, sweet or salty in taste.
Conclusion:
Though, a huge number of scientists sacrificed their lives in order to find the taste of Potassium cyanide, but it remained a mystery for long, until and unless a goldsmith from India named MP Prasad in an attempt to commit suicide with the help of Potassium cyanide could finally reveal the taste of Potassium cyanide. As per the suicide note of him the taste of Potassium Cyanide is very much acrid, that is irritatingly harsh and sharp. This fact about the taste of Potassium cyanide is approved by the World Health Organization and is marked as an extraordinary discovery in the field of science.
Source:
http://www.biotechblog.org/entry/mystery-cyanide-taste/
Editorial: Proposed cuts in state funding for NC Biotechnology Center would … – Winston-Salem Journal
By Dr. Matthew Watson
Editorial: Proposed cuts in state funding for NC Biotechnology Center would ... Winston-Salem Journal The governor's proposed budget would cut $10 million from the N.C. Biotechnology Center's $17.2 million annual appropriation over each of the next two years, the Journal's Richard Craver reported. The nonprofit center, whose only funding resource is ... |
Top Photos & Videos – News & Observer
By Dr. Matthew Watson
![]() NewNet | Top Photos & Videos News & Observer A fledgling agricultural biotechnology company founded by a group of industry veterans and serial entrepreneurs has raised $14.5 million in venture capital financing in spite of a notoriously tough funding environment. “It's a testament to how good the ... RTP agri-tech bags $14.5M for crop researchTriangle Business Journal AgBiome Adds $14.5M for Agricultural ProductsPrivate Equity Hub (press release) |